Please assess the completion status of the following clinical trial:

Trial Title: Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colorectal cancer~* Locally advanced and/or metastatic colorectal cancer~* Have prior chemotherapy as first line treatment~* No prior irinotecan administration~* Able to take oral medication~* Age 20 to 75~* Performance status 0 or 1 (ECOG)~* WBC 3,000-12,000 / mm\^3~* Platelet ≥100,000 / mm\^3~* AST and ALT ≤ 100 IU/L~* Creatinine ≤ 1.2 mg/dL~* Bilirubin ≤ 1.5 mg/dL~Exclusion Criteria:~* Prior radio therapy for colorectal cancer~* Other malignancies in the past 5 years~* Serious illness or medical condition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CPT-11 and TS-1
- 2 (Type: ACTIVE_COMPARATOR): CPT-11, 5-FU and l-LV

Based on this trial design, predict the completion outcome and termination type (if applicable).